Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GST101 in Participants With RAS-Mutant Advanced Solid Tumors

NCT07868172 is registered in ClinicalTrials.gov with Genuine Seed Therapeutics (Zhuhai) Co., Ltd. as lead sponsor.

NCT NCT07868172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07868172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GST101 in Participants With RAS-Mutant Advanced Solid Tumors
Lead sponsor
Genuine Seed Therapeutics (Zhuhai) Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2028
Enrollment
172 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ras-mutant advanced solid tumors